vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and SUNation Energy, Inc. (SUNE). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $27.2M, roughly 1.2× SUNation Energy, Inc.). On growth, SUNation Energy, Inc. posted the faster year-over-year revenue change (77.0% vs -23.8%). Over the past eight quarters, SUNation Energy, Inc.'s revenue compounded faster (43.5% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Suncor Energy Inc. is a Canadian integrated energy company based in Calgary, Alberta. It specializes in production of synthetic crude from oil sands. In the 2020 Forbes Global 2000, Suncor Energy was ranked as the 48th-largest public company in the world.

DNA vs SUNE — Head-to-Head

Bigger by revenue
DNA
DNA
1.2× larger
DNA
$33.4M
$27.2M
SUNE
Growing faster (revenue YoY)
SUNE
SUNE
+100.8% gap
SUNE
77.0%
-23.8%
DNA
Faster 2-yr revenue CAGR
SUNE
SUNE
Annualised
SUNE
43.5%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
SUNE
SUNE
Revenue
$33.4M
$27.2M
Net Profit
$2.6M
Gross Margin
40.7%
Operating Margin
-211.9%
10.7%
Net Margin
9.6%
Revenue YoY
-23.8%
77.0%
Net Profit YoY
138.2%
EPS (diluted)
$-1.41
$105.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
SUNE
SUNE
Q4 25
$33.4M
$27.2M
Q3 25
$38.8M
$19.0M
Q2 25
$49.6M
$13.1M
Q1 25
$48.3M
$12.6M
Q4 24
$43.8M
$15.4M
Q3 24
$89.0M
$14.7M
Q2 24
$56.2M
$13.5M
Q1 24
$37.9M
$13.2M
Net Profit
DNA
DNA
SUNE
SUNE
Q4 25
$2.6M
Q3 25
$-80.8M
$-393.0K
Q2 25
$-60.3M
$-9.6M
Q1 25
$-91.0M
$-3.5M
Q4 24
$-6.8M
Q3 24
$-56.4M
$-3.3M
Q2 24
$-217.2M
$-6.9M
Q1 24
$-165.9M
$1.2M
Gross Margin
DNA
DNA
SUNE
SUNE
Q4 25
40.7%
Q3 25
38.0%
Q2 25
37.0%
Q1 25
35.1%
Q4 24
36.4%
Q3 24
35.6%
Q2 24
35.4%
Q1 24
36.4%
Operating Margin
DNA
DNA
SUNE
SUNE
Q4 25
-211.9%
10.7%
Q3 25
-231.8%
-1.3%
Q2 25
-132.1%
-16.6%
Q1 25
-184.1%
-17.2%
Q4 24
-236.3%
-42.3%
Q3 24
-62.0%
-10.9%
Q2 24
-396.7%
-15.0%
Q1 24
-469.1%
-16.5%
Net Margin
DNA
DNA
SUNE
SUNE
Q4 25
9.6%
Q3 25
-207.9%
-2.1%
Q2 25
-121.6%
-73.5%
Q1 25
-188.2%
-27.7%
Q4 24
-44.4%
Q3 24
-63.3%
-22.4%
Q2 24
-386.4%
-51.2%
Q1 24
-437.3%
9.1%
EPS (diluted)
DNA
DNA
SUNE
SUNE
Q4 25
$-1.41
$105.59
Q3 25
$-1.45
$-0.12
Q2 25
$-1.10
$-3.14
Q1 25
$-1.68
$-106.71
Q4 24
$-1.91
$41676.94
Q3 24
$-1.08
$-2350.12
Q2 24
$-4.23
$-11022.91
Q1 24
$-3.32
$-38414.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
SUNE
SUNE
Cash + ST InvestmentsLiquidity on hand
$422.6M
$7.2M
Total DebtLower is stronger
$6.6M
Stockholders' EquityBook value
$508.6M
$24.3M
Total Assets
$1.1B
$48.2M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
SUNE
SUNE
Q4 25
$422.6M
$7.2M
Q3 25
$495.5M
$5.4M
Q2 25
$559.4M
$3.2M
Q1 25
$325.3M
$1.4M
Q4 24
$561.6M
$839.3K
Q3 24
$616.2M
$1.1M
Q2 24
$730.4M
$1.0M
Q1 24
$840.4M
$1.8M
Total Debt
DNA
DNA
SUNE
SUNE
Q4 25
$6.6M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DNA
DNA
SUNE
SUNE
Q4 25
$508.6M
$24.3M
Q3 25
$559.8M
$21.7M
Q2 25
$613.0M
$22.1M
Q1 25
$647.4M
$14.8M
Q4 24
$716.1M
$8.5M
Q3 24
$797.9M
$13.1M
Q2 24
$833.1M
$-10.9M
Q1 24
$987.3M
$-11.2M
Total Assets
DNA
DNA
SUNE
SUNE
Q4 25
$1.1B
$48.2M
Q3 25
$1.2B
$49.6M
Q2 25
$1.2B
$44.1M
Q1 25
$1.3B
$44.4M
Q4 24
$1.4B
$45.7M
Q3 24
$1.5B
$51.0M
Q2 24
$1.6B
$52.9M
Q1 24
$1.6B
$54.7M
Debt / Equity
DNA
DNA
SUNE
SUNE
Q4 25
0.27×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
SUNE
SUNE
Operating Cash FlowLast quarter
$-47.7M
$2.1M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
SUNE
SUNE
Q4 25
$-47.7M
$2.1M
Q3 25
$-31.6M
$2.4M
Q2 25
$-40.3M
$-130.2K
Q1 25
$-51.5M
$-3.4M
Q4 24
$-42.4M
$-1.9M
Q3 24
$-103.5M
$-968.1K
Q2 24
$-84.4M
$-776.4K
Q1 24
$-89.3M
$-2.6M
Free Cash Flow
DNA
DNA
SUNE
SUNE
Q4 25
$-47.7M
Q3 25
$2.4M
Q2 25
$-40.3M
Q1 25
$-59.1M
Q4 24
$-56.1M
$-1.9M
Q3 24
$-118.6M
$-980.3K
Q2 24
$-111.4M
$-788.4K
Q1 24
$-96.0M
$-2.7M
FCF Margin
DNA
DNA
SUNE
SUNE
Q4 25
-142.8%
Q3 25
12.5%
Q2 25
-81.2%
Q1 25
-122.4%
Q4 24
-128.0%
-12.4%
Q3 24
-133.2%
-6.7%
Q2 24
-198.2%
-5.8%
Q1 24
-252.9%
-20.1%
Capex Intensity
DNA
DNA
SUNE
SUNE
Q4 25
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.1%
Q1 25
15.8%
Q4 24
31.3%
0.0%
Q3 24
16.9%
0.1%
Q2 24
48.1%
0.1%
Q1 24
17.7%
0.0%
Cash Conversion
DNA
DNA
SUNE
SUNE
Q4 25
0.81×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-2.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

SUNE
SUNE

Transferred At Point In Time$15.1M55%
Hawaii Energy Connection$10.0M37%
Transferred Over Time$2.1M8%

Related Comparisons